Biotech Values

[DewDiligence]

What is the next great hope for wet-AMD? It’s not REGN’s Eylea, which is not significantly better than Lucentis. It might be Fovista, the anti-PGDF drug from the private company, Ophthotech (#msg-76562000).

Another candidate for the honor that is under the radar screen of most investors is AGN-150998, an anti-VEGF “DARPin” in phase-2 that AGN licensed from the private company, Molecular Partners AG.

This is the clinicaltrials.gov entry for AGN-150998: http://www.clinicaltrials.gov/ct2/show/NCT01397409 .